Access to liposomal generic formulations: beyond AmBisome and Doxil/Caelyx
AbstractThe lack of clear regulatory guidance remains a key bottleneck for securing a second quality-assured source of liposomal amphotericin B (LAmB), the WHO-recommended drug for visceral leishmaniasis. The approval of the first generic liposomal product by the US Food and Drug Administration in February 2013 could be a turning point, and serve as a basis for WHO to develop guidance for the evaluation of generic liposomal formulations.
PublisherPro Pharma Communications International
DescriptionTo access this article, click on "Additional Links".